T-DM1, also known as Trastuzumab Emtansine, is a targeted cancer therapy designed to treat HER2-positive breast cancer. It combines the HER2-targeted action of trastuzumab (Herceptin) with the cytotoxic activity of DM1, a potent chemotherapy agent, allowing for precise delivery of the drug to cancer cells.
